Technical Analysis for WVE - WAVE Life Sciences Ltd.

Grade Last Price % Change Price Change
C 5.67 -12.77% -0.83
WVE closed down 12.77 percent on Monday, March 18, 2024, on 1.88 times normal volume.
Earnings due: Mar 20
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Golden Cross Bullish -12.77%
1,2,3 Pullback Bullish Bullish Swing Setup -12.77%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -12.77%
Pocket Pivot Bullish Swing Setup -12.77%
Volume Surge Other -12.77%
Calm After Storm Range Contraction -12.77%
Wide Bands Range Expansion -12.77%
Wide Bands Range Expansion -11.68%
Calm After Storm Range Contraction -17.04%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 18 hours ago
3x Volume Pace about 19 hours ago
Down 10% about 19 hours ago
2x Volume Pace about 19 hours ago
1.5x Volume Pace about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

WAVE Life Sciences Ltd. Description

WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Rare Diseases Medical Genetics Dysfunction Dystrophy Inflammatory Bowel Disease Muscular Dystrophy Huntington's Disease Genodermatoses Duchenne Muscular Dystrophy Duchenne Epidermolysis Bullosa Genetic Genealogy Cytoskeleton Dystrophin

Is WVE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.6699
52 Week Low 3.1501
Average Volume 946,803
200-Day Moving Average 4.83
50-Day Moving Average 4.84
20-Day Moving Average 5.50
10-Day Moving Average 6.36
Average True Range 0.51
RSI (14) 52.61
ADX 37.43
+DI 28.73
-DI 20.78
Chandelier Exit (Long, 3 ATRs) 6.13
Chandelier Exit (Short, 3 ATRs) 5.18
Upper Bollinger Bands 7.52
Lower Bollinger Band 3.47
Percent B (%b) 0.54
BandWidth 73.68
MACD Line 0.54
MACD Signal Line 0.50
MACD Histogram 0.042
Fundamentals Value
Market Cap 675.51 Million
Num Shares 119 Million
EPS -0.84
Price-to-Earnings (P/E) Ratio -6.75
Price-to-Sales 5.45
Price-to-Book 10.21
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.03
Resistance 3 (R3) 7.15 6.81 6.80
Resistance 2 (R2) 6.81 6.46 6.75 6.73
Resistance 1 (R1) 6.24 6.25 6.07 6.12 6.65
Pivot Point 5.91 5.91 5.82 5.85 5.91
Support 1 (S1) 5.34 5.56 5.17 5.22 4.69
Support 2 (S2) 5.00 5.35 4.94 4.61
Support 3 (S3) 4.43 5.00 4.54
Support 4 (S4) 4.31